Martine Carlu- Benasich

I was delighted to participate in two panels at IPEM this year—one on “How AI is rewriting the PE playbooks” alongside Gaël Gibert from Advent and Guillaume Princen from Anthropic, and another on “Investing in the AI revolution” with Lauriane Requena from KKR and Astrid Moullé-Berteaux from Headline. At Seven2, we see AI not as a buzzword, but as a true industrial revolution—akin to electricity in its transformative potential. The real opportunity for private equity isn’t in chasing the next unicorn, but mostly in helping established companies harness AI to drive operational excellence and margin expansion. Our focus is on the “boring” but powerful applications of AI: automating repetitive tasks, optimizing processes, and leveraging proprietary data to revisit business models and create defensible advantages. The question for investors is not whether AI will change the landscape, but whether you want to own the companies before or after that transformation. We’re building the next generation of AI-enabled market leaders and keep an eye on AI-native companies that combine robust AI applications with high-value services. These businesses are particularly attractive for LBO: they already generate EBITDA, have a clear and growing role in supporting traditional companies to adopt AI, and are resilient against being displaced by hyperscalers. Stay tuned for more on how we’re putting this vision into action. #IPEM #PrivateEquity #AI #ValueCreation #Seven2

110

2 commentaires

Fifteen years after graduating from HEC Paris, Stanislas Niox-Chateau returned to campus with a clear message: “user, user, user.” At #HECTalks, the Doctolib founder spoke with candor about the opportunities and limits of AI in healthcare, the urgency of Europe’s shortage of 11 million health workers, and the need to balance ambition with trust. For him, technology must serve patients and practitioners first, while data privacy remains a principle of “zero compromise.” It was a conversation full of energy but also realism, reminding the audience that innovation in healthcare is fragile by naturedependent on people, trust, and systems. And yet, as he insisted, we are still only at “Day One” of what AI can bring to clinical decision-making. Discover the full story here 👉 https://lnkd.in/eh9uRtDT

280

5 commentaires

I am proud to be part of this major project with UNIFARCO, starting in Italy and then expanding across Europe. The goal is to create a “democratic” version of longevity — potentially accessible to everyone — where pharmacies affiliated with UNIFARCO and specifically trained for this project, serve as sort of hub from where several services can be accessed: from laboratory testing with outstanding partners like Cerba HealthCare Italia and BMR Genomics to a team of specialists (physicians, nutritionists, personal trainers, mental coaches) trained directly by us. This makes it possible to deliver a complete Pro-Longevity program that includes: -Advanced laboratory tests -Genetic analyses focused on the aging process combined with lifestyle analysis -Body composition assessments -Microbiome analysis The pharmacist will provide guidance on precision nutraceuticals, while individuals will have access to online specialist consultations (physician, nutritionist, personal trainer, mental coach) to receive a fully personalized longevity program — all while keeping costs and logistical complexity under control. The mental coach will provide ongoing support to help the person integrate lifestyle changes and adopt new habits — elements that are often neglected, yet form the foundation of any effective longevity plan. We will start with a pilot project in September and expand quickly from there. Here an article from Milano Finanza. #LongevityForAll #ProLongevity #HealthyAging #PrecisionHealth #Genetics #Microbiome #HealthInnovation #LongevityScience #HealthyLifestyle #WellnessTech #Nutraceuticals #Healthspan #ActiveAging #FutureOfHealth #PharmacyInnovation #LifeExtension

165

11 commentaires

🎙️ Special IBC 2025 Episode – Retention Zone One of the most interesting conversations I had at IBC this year was with Gilles Domartini, CEO of Cleeng, right after the second edition of Retention Zone Live. We talked about how innovation in subscriptions is shifting — becoming more accessible and more intelligent. 👉 The big headline: Cleeng Pro. ➡️ A simplified way for any mid-sized publisher to launch a subscription service in under 60 minutes. ➡️ With just a few clicks you can create offers, set up a subscription page, consolidate app store data, and enable customer care. ➡️ And the real game changer? The first 10,000 monthly subscribers are free. ➡️ No contracts, no upfront cost — just the freedom to experiment, learn, and grow. For Vimeo users and smaller publishers frustrated by limited analytics, this could open entirely new doors. 👉 The second big announcement: ChurnIQ AI-ssistant. ➡️ Imagine a retention super-expert on demand. You ask: who’s at risk of churning, on which platform, and what’s the revenue impact? You get the answer instantly. ➡️ But more importantly, it doesn’t stop at insights. It suggests proven remedies, integrates with tools like Braze or Mailchimp, and can trigger campaigns automatically. It’s agentic AI in action — analytics flowing directly into decisions and execution. 📲 Finally, Gilles reminded me why we started Retention Zone in the first place: to create a space where the industry can share real challenges and shape better solutions together. That dialogue has already influenced Cleeng’s roadmap, and it shows the power of community in innovation. A guy with a scarf Benedicte Guichard Alexis Gaï Kirstin White Hjalmar Koedijker Joachim Bergman Kamila Palka Enzo Bermond Kübra Güven Chris Welsh #IBC2025 #RetentionZone #Subscriptions #AI #Streaming

37

3 commentaires

Feldhoff & Cie invests in Europe’s most promising female founders Yesterday, Auxxo announced the first closing of Auxxo Female Catalyst Fund II, raising €26 million to invest in early-stage European startups with female founding teams. We are proud to be part of this commitment to expanding access to capital and driving lasting change in the venture landscape. Congratulations to Bettine Schmitz, Dr. Gesa Miczaika, the whole Auxxo Female Catalyst Fund team and all fellow investors who share this vision. Excited to see what we can build together! 

195

23 commentaires